ReviewBiomarker research2025
Emerging strategies and novel therapeutic targets in acute myeloid leukemia: current advances and future directions.
Review in Biomarker research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Screening of peptide inhibitors targeting YAP-TEAD4 interaction: affinity evaluation and anti-AML cell activity.Journal of enzyme inhibition and medicinal chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by dysregulated differentiation and uncontrolled proliferation of myeloid precursor cells. AML is the second most common type of leukemia after acute lymphoblastic leukemia, yet it has the lower survival rates, with only approximately 30% of adult patients surviving five years post-diagnosis. Standard treatment regimens typically include intensive chemotherapy, advances in allogeneic hematopoietic stem cell transplantation (allo-HSCT) have significantly improved outcomes in the treatment of AML. Advances in molecular profiling technologies have significantly enhanced our understanding of the genetic and epigenetic alterations that drive AML, revealing numerous novel therapeutic targets. Consequently, targeted molecular therapies and epigenetic treatments are becoming increasingly important. Moreover, immunotherapy represents a promising therapeutic strategy that has demonstrated considerable potential in the context of AML. This review summarizes new strategies and emerging therapeutic targets in AML, with a particular focus on recent advancements in immunotherapy. It also explores the feasibility of integrating these therapeutic approaches into current treatment paradigms and their potential impact on future clinical practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.